General Information of Drug (ID: DMIVZ3W)

Drug Name
ES-936 Drug Info
Synonyms
192820-78-3; ES 936; UNII-1XI90I177M; 5-METHOXY-1,2-DIMETHYL-3-(4-NITROPHENOXYMETHYL)INDOLE-4,7-DIONE; 5-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione; 1XI90I177M; 5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione; AC1NBNHW; CHEMBL357217; SCHEMBL3991028; CTK8E6509; DTXSID20172879; MolPort-006-168-362; ZINC587989; AKOS024457934; 1H-Indole-4,7-dione, 5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)-; API0010300; DB02400; ES936, > LS-191843; B5514; KS-00000189; J-012477
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
4470790
ChEBI ID
CHEMBL357217
CAS Number
CAS 192820-78-3
TTD Drug ID
DMIVZ3W

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug(s) Targeting Quinone reductase 1 (NQO1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ARQ 761 DMH5CAL Pancreatic cancer 2C10 Phase 2 [2]
Coenzyme Q10 analog DMO0VGH Huntington disease 8A01.10 Phase 2 [3]
BioE-743 DM7PT8R Leigh syndrome 5C53.24 Phase 2 [4]
Flavin-Adenine Dinucleotide DM5S4GK Discovery agent N.A. Investigative [5]
NSC-645808 DMMBAR3 Discovery agent N.A. Investigative [6]
NSC-106080 DMR6P9S Discovery agent N.A. Investigative [7]
NSC-99528 DMXZAIG Discovery agent N.A. Investigative [7]
NSC-354279 DMVL51I Discovery agent N.A. Investigative [6]
Duroquinone DML7YPS Discovery agent N.A. Investigative [5]
Ethyl Bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate DMJQTIK Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Quinone reductase 1 (NQO1) TT8XK6L NQO1_HUMAN Inhibitor [1]

References

1 Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) ... J Med Chem. 2007 Nov 15;50(23):5780-9.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Therapeutic strategies for Leber's hereditary optic neuropathy: A current update. Intractable Rare Dis Res. 2013 November; 2(4): 130-135.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
6 In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.
7 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
8 Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56.